Caidya, a US-based clinical research organisation focused on accelerating clinical development for biopharmaceutical companies, has appointed Michael Clay as Chief Operating Officer according to a Business Wire report.

Clay will lead Caidya's global operational delivery, client engagement model and execution strategy, further strengthening the company's ability to serve innovative biopharma sponsors across the US, Europe and Asia-Pacific. Clay brings a distinguished track record in global project delivery and site relationship strategy, having led large-scale global programmes across 60-plus countries and built high-performing delivery organisations known for operational rigour and sponsor trust.

Notably, Clay has extensive leadership experience across Asia-Pacific, where speed, regulatory nuance and close site collaboration are critical to success. His hands-on approach to site partnerships and regional execution aligns closely with Caidya's distinct global footprint and its strong presence in China, an increasingly vital region for innovative biotech development and patient access.

Most recently, Clay served as Senior Vice President of Global Project Delivery at Fortrea, where he oversaw more than 500 global clinical trials. His career includes positions as Chief Operating Officer and senior operations roles at other global clinical research organisations and site management organisations.

Barbara Lopez Kunz, CEO of Caidya, stated that Clay's leadership strengthens one of the company's most important differentiators. "Mike's leadership strengthens one of our most important differentiators — our ability to combine global reach with regional expertise, particularly across APAC and China. His deep understanding of site engagement, global execution and sponsor partnership will help us scale whilst preserving the agility, accountability and transparency our clients value," she said.

Access the full announcement on Caidya's Chief Operating Officer appointment in the complete article.